Cervical Cancer and Pap Screening

Necessary cause — oncogenic HPV

• High-risk HPV persistence: Nearly all cervical cancer is attributable to persistent infection with a high-risk HPV type (16, 18, 31, 33, 45, 52, 58). HPV-16 dominates squamous cell carcinoma; HPV-18 is disproportionately represented in adenocarcinoma of the endocervix, which arises above the transformation zone and is therefore more often missed by cytology alone.
• Low-risk types are a distractor: HPV-6 and HPV-11 cause condyloma acuminatum and recurrent respiratory papillomatosis, not cervical cancer.

Modifiable risk factors (what lets infection persist)

• Smoking: tobacco carcinogens concentrate in cervical mucus and deplete Langerhans cells, impairing local viral clearance; risk is dose-dependent and specific to squamous histology.
• Sexual exposure variables: early coitarche, multiple partners, and a high-risk male partner increase the probability of acquiring an oncogenic type; barrier contraception reduces but does not eliminate transmission (skin-to-skin spread).
• Long-term combined oral contraceptive use and high parity: hormonally mediated effects on the transformation zone and on HPV gene expression; risk declines after discontinuation.
• Co-infections: Chlamydia trachomatis, HSV-2, and other STIs promote cervical inflammation and metaplasia.
• Never or under-screened status: the single strongest predictor of invasive disease in the United States — most cancers occur in women who were never screened or lapsed. The CDC/ACIP recommends routine HPV vaccination at age 11–12 (may begin at 9), catch-up through 26, and shared decision-making for ages 27–45.

Non-modifiable risk factors

• Immunosuppression: HIV (especially low CD4), solid-organ transplant, chronic immunosuppressants — impaired clearance drives rapid progression; cervical cancer is an AIDS-defining illness.
• In utero DES exposure: classically clear cell adenocarcinoma of the vagina/cervix, HPV-independent.
• Older age, lower socioeconomic status, and rural or uninsured status: proxies for screening access.

• HPV integration and viral oncogenesis: High-risk HPV strains (16, 18, 31, 33, 45) produce viral oncoproteins E6 and E7 that inactivate tumor suppressors p53 and retinoblastoma (Rb), respectively. E6 promotes p53 degradation via ubiquitin-proteasome pathway, while E7 binds and inactivates Rb, disrupting cell cycle checkpoints and allowing uncontrolled proliferation. Persistent infection (lasting >12-24 months) rather than acute infection drives malignant transformation.

• Stepwise epithelial dysplasia: Cervical cancer develops through progressive stages of cervical intraepithelial neoplasia (CIN): CIN-1 (mild dysplasia), CIN-2/3 (moderate-to-severe dysplasia), and eventually invasive squamous cell carcinoma. This progression occurs over years to decades, allowing detection and treatment at precancerous stages.

• Squamous metaplasia and transformation zone vulnerability: The transformation zone at the squamocolumnar junction undergoes active squamous metaplasia and is most susceptible to HPV-induced neoplastic changes. This is why Pap smears specifically sample the transformation zone.

• Loss of cell differentiation markers: Dysplastic cervical epithelium shows increased nuclear-to-cytoplasmic ratio, hyperchromatic nuclei, coarse chromatin, and loss of normal maturation, reflected in the Bethesda system classification of cytologic abnormalities.

• Additional risk factors amplifying progression: Immunosuppression (HIV/AIDS), smoking, oral contraceptive use, high parity, and concurrent STIs (Chlamydia) increase risk of persistent infection and progression to invasive disease.

• Asymptomatic detection via screening: Most cervical dysplasia and early cancers are detected on routine Pap screening in asymptomatic women, highlighting the critical role of preventive screening in developed healthcare systems.

• Abnormal vaginal bleeding: Post-coital bleeding (bleeding after intercourse), intermenstrual bleeding, or heavy menstrual bleeding can occur with invasive cervical cancer due to friable neoplastic tissue and increased vascularity.

• Vaginal discharge: Blood-tinged, purulent, or foul-smelling vaginal discharge may accompany invasive disease, particularly with necrotic tumor components.

• Pelvic pain and urinary symptoms: Advanced disease may cause pelvic pain, dysuria, urinary frequency, or hematuria if bladder involvement occurs; rectal symptoms develop with posterior spread.

• Late-stage presentations: Weight loss, lower extremity edema or pain (from lymphatic obstruction), and constitutional symptoms indicate advanced disease with regional/distant metastases.

• Clinical pearl—early cancers are often asymptomatic: Symptomatic presentation typically indicates advanced disease (stage IB or higher), emphasizing why screening detects disease at more curable stages.

• Pap smear/cervical cytology: The primary screening test using a spatula and brush to sample the transformation zone, fixed on a slide and examined for dysplastic changes. The Bethesda System 2014 classifies results as: negative for intraepithelial lesion or malignancy (NILM), atypical squamous cells of undetermined significance (ASC-US), low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL), and atypical glandular cells (AGC).

• HPV testing (reflex or co-testing): High-risk HPV DNA testing (by PCR or hybrid capture) identifies women at risk for CIN-2/3 or cancer. HPV reflex testing is performed on ASC-US cytology results; co-testing combines Pap + HPV testing in women ≥30 years and improves detection of precancerous lesions. HPV-positive ASC-US warrants colposcopy, while HPV-negative ASC-US typically results in routine screening resumption.

• Colposcopy and cervical biopsy: Indicated for HSIL, LSIL with HPV positivity, persistent ASC-US with HPV positivity, or abnormal Pap results. The colposcope magnifies the cervix; acetic acid and Lugol's iodine staining identify acetowhite lesions and abnormal vasculature. Biopsies of abnormal areas provide histologic grading (CIN-1, CIN-2, CIN-3) and confirm dysplasia or malignancy.

• Cervical biopsy gold standard: Tissue diagnosis via colposcopy-directed cervical biopsy is required to confirm CIN grade or invasive cancer diagnosis before treatment. Endocervical curettage may be performed if the transformation zone is not fully visualized.

• Staging in invasive disease: MRI pelvis, CT chest/abdomen, PET-CT, and cystoscopy/proctoscopy assess local invasion, regional lymph node involvement, and distant metastases using the FIGO 2009 staging system (stages I–IV based on extent of local, regional, and distant spread).

• Precancerous lesions (CIN-1): Conservative management with repeat cytology or HPV testing in 12 months is appropriate for CIN-1, as ~60% regress spontaneously. Excisional procedures (loop electrosurgical excision procedure [LEEP] or cold knife conization) are reserved for persistent CIN-1 or if adequate colposcopy is not possible.

• Precancerous lesions (CIN-2/3): Excisional procedures (LEEP or cold knife conization) are first-line, providing both treatment and histologic assessment of margins and endocervical involvement. Ablative procedures (laser ablation, cryotherapy) are second-line if margins are negative and invasion is excluded, though excision is preferred to allow margin assessment. Post-treatment surveillance with cytology or HPV testing at 6 weeks, 6 months, and annually for 25 years is mandatory.

• Stage IA invasive cancer (microinvasion): Radical hysterectomy (Wertheim hysterectomy) with bilateral pelvic lymph node dissection is first-line for stage IA1 (<3 mm depth, <7 mm width) with negative margins and no lymphovascular space invasion (LVSI). For women desiring fertility with stage IA1 and favorable prognostic factors, radical trachelectomy with pelvic lymphadenectomy is an option, allowing potential future pregnancies.

• Stage IB–IIA invasive cancer: Concurrent chemoradiation therapy (CCRT) is the gold standard and first-line treatment. Cisplatin 40 mg/m² weekly during external beam radiation therapy (EBRT) to the pelvis (45–50 Gy over 5–6 weeks) followed by intracavitary brachytherapy (80–90 Gy to point A) provides superior survival compared to radiation alone. Alternatively, radical hysterectomy with pelvic/paraaortic lymphadenectomy is an option for select stage IB1 patients without adverse features, though CCRT is standard in many centers.

• Stage IIB–IVA invasive cancer: Concurrent chemoradiation therapy is standard, with EBRT to the pelvis and extended fields (including paraaortic nodes for IIB–IVA), cisplatin chemotherapy, and intracavitary brachytherapy. Surgery is not typically first-line but may be considered for IIB disease in select cases or as consolidation after CCRT.

• Stage IVB (distant metastases): **Platinum-based chemotherapy

Complications of untreated/advanced disease

• Ureteral obstruction and postrenal AKI: parametrial tumor encases the ureters as they pass under the uterine arteries → bilateral hydronephrosis, rising creatinine, hyperkalemia, uremia. Uremia from bilateral ureteral obstruction is the classic cause of death in cervical cancer. Emergency — decompress with percutaneous nephrostomy or ureteral stents before any nephrotoxic chemotherapy.
• Hemorrhage: friable, necrotic exophytic tumor bleeds briskly. Hemodynamic instability with vaginal bleeding is an emergency requiring resuscitation, vaginal packing, and urgent radiation or arterial embolization.
• Fistula formation: tumor necrosis (or prior radiation) erodes into bladder or rectum → continuous painless urine leakage (vesicovaginal) or feculent discharge (rectovaginal); confirm with cystoscopy/imaging.
• Lymphatic and venous obstruction: unilateral leg edema plus sciatic-distribution pain and hydronephrosis is the triad of pelvic sidewall involvement (unresectable disease). Also raises VTE risk — sudden dyspnea warrants PE workup.
• Malignant obstruction/sepsis: pyonephrosis or pelvic abscess in an obstructed system is an emergency.

Complications of treatment

• Excisional procedures (LEEP, cold knife conization): loss of stromal bulk → cervical insufficiency and increased preterm birth and PPROM risk, greatest with deep or repeat excisions (ACOG); also cervical stenosis with hematometra/dysmenorrhea and inadequate future cytologic sampling, plus delayed post-procedure bleeding.
• Radical hysterectomy: autonomic nerve injury → neurogenic bladder with urinary retention; ureteral injury or fistula; lymphocyst and lower-extremity lymphedema after lymphadenectomy.
• Pelvic radiation: acute proctitis/cystitis and diarrhea; late vaginal stenosis and dryness, radiation enteritis with obstruction, hemorrhagic cystitis, pelvic insufficiency fractures, and premature ovarian failure (ovarian transposition is offered to young women per NCCN).
• Cisplatin: nephrotoxicity (give aggressive hydration), ototoxicity, peripheral neuropathy, and myelosuppression — febrile neutropenia is an emergency requiring immediate empiric broad-spectrum antibiotics.

• Screening starts at 21, not at sexual debut: the USPSTF recommends beginning at 21 with cytology every 3 years, and for ages 30–65 either cytology every 3 years, co-testing every 5 years, or primary high-risk HPV testing every 5 years. The ACS 2020 guideline prefers primary HPV testing beginning at age 25. A sexually active 18-year-old needs contraception and STI screening — not a Pap.
• Stopping rules: discontinue at age 65 if prior screening was adequate and negative; stop entirely after total hysterectomy for benign disease. Continue vaginal cuff cytology if the hysterectomy was for CIN-2+ or cancer.
• The immunosuppression exception: women with HIV screen earlier, more frequently, and for life — no age 65 cutoff.
• Best next step after an abnormal Pap is colposcopy with directed biopsy, not treatment. ASCCP 2019 management is risk-based: the combination of current results and history determines whether to observe, do colposcopy, or proceed to expedited excision (immediate LEEP is acceptable for nonpregnant adults with very high immediate CIN-3+ risk, as with HSIL cytology plus HPV-16).
• Pregnancy modifies the workup: colposcopy and biopsy are permitted, but endocervical curettage is contraindicated, and CIN treatment is deferred postpartum unless invasive cancer is suspected.
• Buzzwords: koilocytes (perinuclear halo, raisinoid nucleus) = HPV cytopathic effect; acetowhite lesion with mosaicism and punctation = colposcopic dysplasia; barrel-shaped cervix and postcoital bleeding = invasive disease; p16 diffuse block positivity = high-risk HPV–driven lesion.
• The association examiners love: E6 → p53 degradation, E7 → Rb inactivation; and bilateral hydronephrosis as the terminal event.
• Common distractors: HPV vaccination does not replace screening (it does not cover every oncogenic type); atypical glandular cells (AGC) require endometrial sampling in older or at-risk women, not just colposcopy; and a normal-appearing cervix never excludes dysplasia.